In short
Currently, there is 1 ongoing clinical trial investigating vaccines for Ebola Disease. This trial focuses on understanding long-term immunity and the potential benefits of booster doses for individuals at occupational risk of exposure to the Ebola virus.
Clinical trial locations
Study on the Long-Term Immunity of the Ebola Vaccine VSV-EBOV and Booster Dose for Workers at Risk of Ebola Exposure
This clinical trial is investigating the Ervebo vaccine, which is designed to protect against the Ebola virus. The study aims to understand how long immunity lasts after vaccination and whether an additional booster dose can provide enhanced or prolonged protection for people who may be exposed to the virus through their work.
Main focus: The trial compares immune responses in participants who receive the initial Ervebo vaccination with and without a booster dose given six months later. Researchers will monitor participants for 24 months, measuring antibody levels in the blood to assess how well the vaccine maintains immunity over time. The study also tracks any side effects that occur after vaccination.
Who can participate: To be eligible for this study, you must be at least 18 years old and at risk of coming into contact with the Ebola virus through laboratory work, clinical work, or fieldwork. You must sign an informed consent form showing you understand and agree to participate in the study. Women who can become pregnant must use effective birth control from 30 days before vaccination until 2 months after receiving the vaccine or booster. Participants must also agree to avoid contact with blood and body fluids from high-risk individuals for 6 weeks after vaccination, refrain from donating blood from 30 days before the first vaccination until the study ends, and be willing to be randomly assigned to either receive or not receive a booster shot at the 6-month visit.
Who cannot participate: You cannot join this study if you are not within the specified age range, cannot receive the Ervebo vaccine for medical reasons, are unable to receive a booster shot at 6 months, or belong to a vulnerable population that might require special protection or care.
Investigational treatment: The study uses ERVEBO, a vaccine that works by helping your body build up its immune system defenses against the Ebola virus. Participants receive an initial injection into a muscle, and after six months, some will receive a booster dose while others will not. This approach allows researchers to determine whether the booster dose provides better long-term protection for people at occupational risk of exposure.
What to expect: Upon joining, you will receive the initial Ervebo injection into a muscle. Over the following 24 months, you will attend regular follow-up visits where blood samples may be taken to measure antibody levels. At the 6-month mark, you will be randomly assigned to either receive or not receive a booster dose, administered in the same way as the initial vaccination. Throughout the study, researchers will monitor you for any side effects or health changes, with final assessments conducted at 24 months to evaluate the vaccine's long-term effectiveness.
Summary
Currently, there is one active clinical trial for Ebola Disease, taking place in Germany. This trial focuses specifically on occupational protection, targeting workers at risk of exposure to the Ebola virus through laboratory, clinical, or field work. The research investigates the ERVEBO vaccine's ability to maintain long-term immunity and whether booster doses can enhance protection over time. This study is particularly important for understanding how to best protect healthcare workers and researchers who may encounter the virus in their professional environments.
